Stock Taper
Tevogen Bio Holdings Inc., a Warren-based clinical-stage biotech, develops off-the-shelf T cell therapies for virology, oncology, and neurology, with its lead product TVGN 489 targeting acute COVID-19 and long COVID patients.

Tevogen Bio's lead clinical-stage, off-the-shelf T cell therapy, which has completed Phase 1 for high-risk COVID-19 and is being developed for Long COVID, is the company's primary therapeutic focus.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
DWTX | $2.65 | COMPARE |
CING | $5.33 | COMPARE |
MRKR | $1.37 | COMPARE |
COCP | $1.10 | COMPARE |
PHIO | $1.13 | COMPARE |
INAB | $1.03 | COMPARE |
IMRN | $1.15 | COMPARE |
EVGN | $0.55 | COMPARE |